WASHINGTON, D.C. — The Food and Drug Administration (FDA) this week approved a new vaccine, Capvaxive, to combat invasive diseases and pneumonia caused by Streptococcus pneumoniae in adults.

recommends that all children younger than 5 years old get the vaccine, as well as children 5 through 18 years old with certain risk conditions. The germs responsible for pneumococcal infections are ...

Antimicrobial resistance and serotypes in Streptococcus pneumoniae have been evolving with the widespread use of antibiotics and the introduction of pneumococcal conjugate vaccines (PCV).

The vaccine protects against the serotypes responsible for the majority of adult invasive pneumococcal disease ...

I am incredibly proud of the entire Vaxcyte team for these achievements.” “Despite current vaccination efforts, Streptococcus pneumoniae is the leading cause of vaccine-preventable deaths globally in ...

GlaxoSmithKline has agreed a $3.3 billion takeover of US biotech Affinivax, buying a pneumococcal vaccine candidate ... of the common serotypes of Streptococcus pneumoniae – a bacteria which ...

Pneumococcal Meningitis Pneumococcus, also known as Streptococcus pneumoniae, is a type of bacteria ... or intellectual disability. Vaccines can protect against a number of different forms of ...

A common bacterium, Streptococcus pneumoniae, lives in the respiratory ... a leading cause of immediate death among AIDS patients. Vaccines against certain kinds of pneumonia exist for adults ...

Pneumococcal species are the most common causative pathogens for pneumonia in the elderly, and the development and utilization of the pneumococcal vaccine was a major public health milestone.